Tempest Therapeutics Inc (TPST NASDAQ) stock market data APIs
$9.5531
0.56(5.9%)
as of September 17, 2025
Try our APIs with
free plan!
Tempest Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
Prev. Close
9.5531
Open
10.1144
High
10.2041
Low
9.6279
52 wk Range
5.3495-20.67
Market Cap
42 537 K
Shares Outstanding
4 440 K
EPS
-2.07
Beta
-2.291
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tempest Therapeutics Inc data using free add-ons & libraries
Get Tempest Therapeutics Inc Fundamental Data
Tempest Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -43 091 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-11
- EPS/Forecast: -0.28
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tempest Therapeutics Inc News
New
Vividion Therapeutics Appoints Sam Whiting, M.D., Ph.D., as Chief Medical Officer
Dr. Whiting brings extensive experience in medical oncology spanning patient care, early drug discovery, and late-stage global development activities His leadership will deepen the company’s clinica...
Tempest Therapeutics GAAP EPS of -$2.07 beats by $0.58
* Tempest Therapeutics press release [https://seekingalpha.com/pr/20196689-tempest-reports-second-quarter-2025-financial-results-and-provides-business-update] (NASDAQ:TPST [https://seekingalpha.com/...
Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update
Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in ChinaGranted orphan drug designation from the European Medicines Agen...
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
Builds on clearances already received by FDA and EMAChina has the largest population of patients with hepatocellular carcinoma in the world BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempe...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
